6-1-2019

Menstrual cycle-associated modulations in neuromuscular function and fatigability of the knee extensors in eumenorrheic women

Paul Ansdell
Northumbria University

Callum G. Brownstein
Northumbria University

Jacob Skarabot
Northumbria University

Kristy M. Hicks
Northumbria University

Davina C.M. Somoes
Northumbria University

See next page for additional authors

Authors

Paul Ansdell, Callum G. Brownstein, Jacob Skarabot, Kristy M. Hicks, Davina C.M. Somoes, Kevin Thomas, Glyn Howatson, Sandra K. Hunter, and Stuart Goodall

Menstrual cycle-associated modulations in neuromuscular function and fatigability of the knee extensors in eumenorrheic women

Paul Ansdell
Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom
Callum G. Brownstein
Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom
Université Lyon, UJM-Saint-Etienne, Inter-university Laboratory of Human Movement Biology, Saint-Etienne, France
Jakob Škarabot
Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom

Kirsty M. Hicks
Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom
Davina C. M. Simoes
Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom

Kevin Thomas

Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom

Glyn Howatson

Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom
Water Research Group, School of Environmental Sciences and Development, Northwest University, Potchefstroom, South Africa

Sandra K. Hunter

Exercise Science Program, Department of Physical Therapy, Marquette University, Milwaukee, Wisconsin

Stuart Goodall

Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom

Abstract

Sex hormone concentrations of eumenorrheic women typically fluctuate across the menstrual cycle and can affect neural function such that estrogen has neuroexcitatory effects, and progesterone induces inhibition. However, the effects of these changes on corticospinal and intracortical circuitry and the motor performance of the knee extensors are unknown. The present two-part investigation aimed to *1*) determine the measurement error of an exercise task, transcranial magnetic stimulation (TMS)-, and motor nerve stimulation (MNS)-derived responses in women ingesting a monophasic oral contraceptive pill (hormonally-constant) and *2*) investigate whether these measures were modulated by menstrual cycle phase (MCP), by examining them before and after an intermittent isometric fatiguing task (60% of maximal voluntary contraction, MVC) with the knee extensors until task failure in eumenorrheic women on days 2, 14, and 21 of the menstrual cycle. The repeatability of neuromuscular measures at baseline and fatigability ranged between moderate and excellent in women taking the oral contraceptive pill. MVC was not affected by MCP ($P = 0.790$). Voluntary activation (MNS and TMS) peaked on day 14 ($P = 0.007$ and 0.008, respectively). Whereas corticospinal excitability was unchanged, short-interval intracortical inhibition was greatest on day 21 compared with days 14 and 2 ($P < 0.001$). Additionally, time to task failure was longer on day 21 than on both days 14 and 2 (24 and 36%, respectively, $P = 0.030$). The observed changes were larger than the associated measurement errors. These data demonstrate that neuromuscular function and fatigability of the knee extensors vary across the menstrual cycle and may influence exercise performance involving locomotor muscles.

NEW & NOTEWORTHY The present two-part study first demonstrated the repeatability of transcranial magnetic stimulation- and electrical motor nerve stimulation-evoked variables in a hormonally constant female population. Subsequently, it was demonstrated that the eumenorrheic menstrual cycle affects neuromuscular function. Changing concentrations of neuroactive hormones corresponded to greater voluntary activation on day 14, greater intracortical inhibition on day 21, and lowest fatigability on day 21. These alterations of knee extensor neuromuscular function have implications for locomotor activities.

INTRODUCTION

The cyclical changes in concentrations of multiple sex hormones, including estrogen and progesterone ([55](#)), across the eumenorrheic menstrual cycle can affect central nervous system (CNS) function due to their ability to cross the blood-brain barrier ([62](#)). In vitro models have shown direct evidence for the effect of sex hormones on neuronal function. For instance, estradiol (an estrogenic steroid hormone) binds to estrogen receptor-α (ERα) sites on γ-aminobutyric acid (GABA)-mediated neurons, causing an attenuation in GABA synthesis and release ([54](#), [70](#)). Additionally, estrogen potentiates the effects of excitatory glutamatergic [both *N*-methyl-d-aspartate (NMDA) and non-NMDA] receptors ([61](#)), resulting in a net excitatory effect. Additionally, estrogen has been shown to decrease firing thresholds and increase discharge frequency of cerebral neurons ([58](#), [72](#)). On the contrary, progesterone has a net inhibitory effect on the nervous system, as the activity and effects of GABA are potentiated, leading to decreased neuronal discharge rate ([60](#)) and increased inhibition of pyramidal neurons in

rats ([37]). Some evidence also suggests that the presence of progesterone directly antagonizes estrogenic actions by lowering the available ERα and ERβ receptor numbers on various sites of neuronal cells ([47]). Indeed, as Smith and Woolley ([61]) outlined, the neurosteroidal actions of hormones act on the neurotransmitter receptors. Thus, given that GABAergic and glutamatergic synapses are located within the motor cortex ([43]), a hormonal effect would be expected.

The differential effect of estrogen and progesterone concentrations on indexes of nervous system excitability has also been established in humans. Transcranial magnetic stimulation (TMS) studies show increased intracortical excitability and reduced intracortical inhibition in the late-follicular phase, when estradiol concentration is high and progesterone low ([56], [57]), substantiating the alterations seen in the aforementioned in vitro studies. While these in vivo studies show clear changes in human CNS function, they were conducted in the resting upper limbs, specifically in hand muscles associated with fine motor control. However, properties of intracortical and corticospinal circuits vary between upper and lower limb projections ([7], [15]). Thus, the menstrual cycle-associated modulations in neural function of a small upper limb muscle group cannot be extrapolated to larger, lower limb muscle groups. Understanding how the menstrual cycle affects the neural control of large locomotor muscle groups has significant implications for everyday locomotive tasks, injury rehabilitation, and athletic performance. For instance, neuroplasticity following stroke ([17]) and strength training ([71]) are influenced by GABAergic inhibition.

To date, there is minimal research investigating menstrual cycle-induced changes in the nervous system and motor function of the knee extensors (KE). Previous studies investigating motor function, such as the ability to produce maximum voluntary contraction force (MVC), are equivocal, with studies showing 8–23% greater maximal force with the KE midcycle ([4], [53], [64]). Multiple studies, however, report no difference in maximal strength ([20], [24], [40], [46]). The studies that have shown changes in maximal strength have suggested that mechanisms such as motor unit firing rates ([65]) and intracortical excitability ([56], [57]) could be contributing factors. However, the proposed mechanistic factors, and the neuromuscular response (e.g., MVC), have not been concurrently studied. Voluntary activation (VA) of the quadriceps muscle has been assessed using motor nerve stimulation twice with no menstrual cycle effect shown ([40], [46]). However, as it is thought that the assessment of VA using TMS (VA_{TMS}) reflects the ability of the motor cortex to activate the motor units within the target muscle group ([68]), if supraspinal properties are modulated by the menstrual cycle ([56], [57]), VA_{TMS} could provide a more appropriate measure to discern whether the ability to voluntarily activate the KE is affected.

Other aspects of motor performance, such as performance fatigability ([38]), have also been studied throughout the menstrual cycle with inconclusive results. Sarwar et al. ([53]) showed that the KE of eumenorrheic women were less fatigable in the luteal phase during an electrically stimulated, isometric fatiguing protocol. However, this finding has not been corroborated with dynamic voluntary contractions performed with the KE ([21], [40]). Additionally, none of the aforementioned studies were open-ended, with a fatigue index calculated after a set amount of time/contractions. Thus, due to the causes of fatigability being task specific ([66]), discrepancies in the aforementioned investigations could have been due to the differences in fatiguing protocols used and their respective limiting factors.

The effect of hormonal fluctuations on neuromuscular function and fatigability of the KE remains unclear. Conflicting literature exists for the majority of neuromuscular variables despite a rationale for change based on neuroendocrine and upper limb studies. The inclusion of statistical measures of error is recommended for investigations utilizing methods of neurostimulation to inform the contribution of random variation to any modifications in neuromuscular function ([29]). Therefore, the present investigation recruited a population of monophasic oral contraceptive (mOCP) users to discern test-retest repeatability of neuromuscular function measures without the influence of endogenous hormones (*Study A*). The consistent dosage of exogenous estrogen and progesterone in the mOCP precludes ovulation ([28]), creating a physiological environment in which the effects of endogenous hormones are negated. Thereafter, *Study B* aimed to investigate KE neuromuscular function and fatigability across the menstrual cycle. It was hypothesized that when estrogen levels increased

(and progesterone remained low) from day 2 to day 14, maximum force production would concomitantly rise alongside a reduction in intracortical inhibition and an increase in VA. Second, it was hypothesized that the rise in progesterone from day 14 to day 21 would occur alongside a reversal in these changes and improved time to task failure (TTF).

METHODS

Ethical Approval

This study received institutional ethical approval from the Northumbria University Health and Life Sciences Research Ethics Committee (HLSPA301116) and was conducted according to all aspects of the Declaration of Helsinki, apart from registration in a database. Participants provided written, informed consent to volunteer for the study.

Participants

A total of 30 participants volunteered to participate in the study. Fifteen mOCP users (age: 23 ± 2 yr; stature: 170 ± 6 cm; mass: 70.6 ± 8.5 kg) and 15 eumenorrheic women (age: 25 ± 4 yr; stature: 169 ± 6 cm; mass: 68.3 ± 7.8 kg; mean cycle duration: 29 ± 3 days, range: 24–34 days). The mOCPs reported taking a mOCP for at least 6 mo as prescribed (i.e., a 7-day break after every 21-day pill consumption period), whereas eumenorrheic women reported having regular cycles without using any form of hormonal contraceptives for at least 6 mo. A full list of the mOCPs taken by participants is presented in Table 1. Participants arrived at the laboratory rested and hydrated, with strenuous physical activity avoided for 48 h and caffeine and alcohol prohibited for 24 h.

Table 1. mOCPs taken by participants in Study A					
mOCP Brand	No. Participants	Synthetic Estrogen	Dosage, µg	Synthetic Progestin	Dosage, µg
Rigevidon	6	Ethinylestradiol	30	Levonorgestrel	150
Cilest	3	Ethinylestradiol	35	Norgestimate	250
Yasmin	2	Ethinylestradiol	30	Drospirenone	300
Gedarel	1	Ethinylestradiol	20	Desogestrel	150
Gedarel	1	Ethinylestradiol	30	Desogestrel	150
Microgynon	1	Ethinylestradiol	30	Levonorgestrel	150
Levest	1	Ethinylestradiol	30	Levonorgestrel	150

mOCP, monophasic combined oral contraceptive pills.

Experimental Design

Study A.

Oral contraceptive users visited the laboratory three times, completing a familiarization and two experimental visits. Experimental visits were completed during the final 14 days of the pill cycle, with a minimum of 48 h

between visits to allow recovery ([13](#)). The visits were identical to those described below for *Study B*; however, blood sampling was not performed, as it is established that endogenous hormone concentrations do not fluctuate throughout the consumption phase of the mOCP cycle ([10](#)).

Study B.
Eumenorrheic women visited the laboratory four times, completing a familiarization session before three experimental visits. Participants completed experimental visits on days 2 (D2, early follicular), 14 (D14, late follicular), and 21 (D21, midluteal) of the menstrual cycle. Testing days were counted from the onset of menstruation and, to verify menstrual cycle phase, fasted venous blood samples were taken between the hours of 0600 and 0900 on testing days to analyze serum estradiol and progesterone concentrations. The order of visits was pseudorandomized and counterbalanced to minimize order effects, with five participants beginning on each testing day (D2, D14 or D21). All testing visits occurred within the same menstrual cycle (order: D2, D14, D21), or two consecutive cycles (order: D14, D21, D2 or D21, D2, D14). Experimental visits consisted of a baseline neuromuscular assessment, intermittent, isometric contractions at 60% MVC until task failure, followed immediately by a post-task neuromuscular assessment. The intensity for the fatiguing task was likely far greater than the critical torque [~30% MVC ([12](#))], and, therefore, an unsustainable intensity, with task failure attributable to decrements in neuromuscular function ([1](#), [11](#)).

Experimental Procedures
For *Study B*, upon arrival between the hours of 0600 and 0900, fasted venous blood samples were taken following 10 min of seated rest. Participants were then instructed to consume a typical breakfast and return to the laboratory at their designated testing time. The breakfast and time of testing were replicated (±1 h) for each experimental visit to control for diurnal variations in corticospinal excitability and maximal force production ([63](#)). Time of testing was also controlled for in *Study A*, with participants consuming the mOCP a constant time before trials to standardize circulating exogenous hormone concentrations between visits. In both studies, experimental sessions began with participants completing a standardized voluntary isometric contraction warm-up (2 × contractions at 25, 50, and 75% perceived maximal effort) followed by a baseline neuromuscular assessment (described below). The fatiguing task involved sets of intermittent isometric contractions (3-s contraction, 2-s rest at 60% MVC) to task failure. Contractions were paced with an audible metronome to ensure the duty cycle was maintained. One set was defined as 11 submaximal contractions followed by a 3-s MVC with motor nerve stimulation (MNS) delivered at the peak force and 2 s post, lasting 1 min. Task failure was defined as an inability to reach the target force three times at any stage of the protocol. Rating of perceived exertion [RPE ([6](#))] was recorded using a 6–20 scale following each MVC throughout the fatiguing task. Real-time visual force feedback using target forces set as percentages of maximum force was provided to participants on a computer screen to aid a constant force level. The post-task neuromuscular assessment began immediately following task failure.

Neuromuscular assessments.
Measures of neuromuscular function were assessed pre- and postexercise with MNS of the femoral nerve and TMS of the contralateral motor cortex at rest and during voluntary contractions of the right knee extensors. Preexercise neuromuscular assessments began with two practice MVCs to ensure potentiation of subsequent evoked measures, followed by three ~3-s MVCs, all separated by 30 s. During these three MVCs, MNS was delivered when peak force plateaued and then ~2 s after the MVC to measure voluntary activation (VA_{MNS}) and potentiated twitch amplitude ($Q_{tw.pot}$) of the knee extensors. Single-pulse TMS was subsequently delivered during two sets of five 3- to 5-s contractions at 100, 87.5, 75, 62.5, and 50% MVC, with 5-s rest between contractions and 10-s rest between sets, to determine VA_{TMS} ([19](#)). The TMS silent period (SP) was determined during the 50% MVC contraction of each set. Participants were instructed to maintain a constant force on the guideline and "push through the stimulation" ([52](#)). Finally, 10 single- and 10 paired-pulse TMS stimulations were delivered during a 10% MVC contraction in an alternate order to determine corticospinal excitability and short-interval cortical inhibition (SICI), respectively. The neuromuscular assessment was repeated immediately postexercise. Measures of neuromuscular function (MVC, $Q_{tw.pot}$, VA_{MNS}) were measured within 30 s of task

failure, and VA_{TMS} measured within 2–2.5 min, in an attempt to minimize the dissipation of fatigue. However it is possible that the sensitivity of these measures was compromised due to the rapid recovery of central fatigue postexercise (32).

Force and electromyographical recordings.

During assessments of neuromuscular function and fatiguing tasks, participants sat on a custom-built chair with knee and hip angles kept constant (both 90° flexion). A calibrated load cell (MuscleLab force sensor 300; Ergotest Technology, Porsgrunn, Norway) was attached via a noncompliant cuff positioned 2 cm superior to the ankle malleoli on the participants' right leg, to measure knee extensor force (N). Surface Ag/AgCl electrodes (Kendall H87PG/F; Covidien, Mansfield, MA) were placed over the rectus femoris (RF), and biceps femoris (BF) muscles with a 2-cm interelectrode distance to record the compound muscle action potential (M-wave) elicited by the electrical stimulation of the femoral nerve, the motor-evoked potential (MEP) elicited by TMS, and the root-mean-square amplitude during isometric contractions (rmsEMG). Electrode placement was consistent with SENIAM (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles) guidelines (35), and a reference electrode was placed over the patella. Prior to placement, the skin-electrode contact area was cleaned using a 70% IPA alcohol wipe (FastAid; Robinson Healthcare, Worksop, UK). Signals were amplified: gain × 1,000 for EMG and × 300 for force (CED 1902; Cambridge Electronic Design, Cambridge, UK), bandpass filtered (EMG only: 20–2,000 Hz), digitized (5 kHz CED 1401, Cambridge Electronic Design), and analyzed offline (Spike2 v.8, Cambridge Electronic Design).

Motor nerve stimulation.

Single electrical stimuli (200 µs duration) were delivered to the right femoral nerve using a constant current stimulator (DS7AH Digitimer; Welwyn Garden City, UK) via adhesive surface electrodes (CF3200; Nidd Valley Medical, Harrogate, UK). The cathode was placed over the nerve, high in the femoral triangle, in the position that elicited the greatest twitch amplitude (Q_{tw}) and M-wave in the RF at rest. The anode was placed halfway between the greater trochanter and the iliac crest. Optimum stimulus intensity was determined as the minimum current that elicited maximum values of Q_{tw} and M-wave (M_{max}) at rest. To ensure a supramaximal stimulus, the optimum stimulus intensity was increased by 30% and was not different between trials in either study (*A*: 230 ± 61 vs. 241 ± 65 mA, *P* = 0.271; *B:* 233 ± 72, 244 ± 68, and 262 ± 67 mA, *P* = 0.125).

Transcranial magnetic stimulation.

Single and paired pulse stimuli (1 ms duration) were delivered to the contralateral (left) motor cortex via a concave double cone coil (110 mm diameter, maximum output 1.4 T) powered by two linked monopulse stimulators (Magstim Bistim and Magstim[200]; Magstim, Whitland, UK). Optimal coil placement was determined as the position that elicited the greatest RF MEP with concomitant smallest antagonist (BF) MEP during a 10% MVC at 50–70% stimulator output. This position was marked on the scalp with indelible marker to ensure consistent placement during trials. Stimulator intensity for VA_{TMS} was determined as the intensity that elicited the greatest superimposed twitch (SIT) during a contraction at 50% MVC. Stimulator intensity was increased in 5% intervals from 50% stimulator output, and two stimuli were delivered during an ~5 s contraction, with the mean of two SITs recorded (9, 18). Mean stimulator intensity was not different between trials in either study (*A*: 67 ± 10 vs. 66 ± 10%, *P* = 0.737; *B*: 63 ± 10, 63 ± 11 and 63 ± 12%, *P* = 0.984). The stimulator output activated a large proportion of the KE motoneuron pool at baseline in each experimental visit with no difference between trials in *Study A* (69 ± 35 vs. 68 ± 36% M_{max} amplitude, *P* = 0.916) or *Study B* (61 ± 17, 57 ± 17, 55 ± 14% M_{max} amplitude, *P* = 0.788). Small coactivation of the antagonist muscle (BF) was observed in response to TMS and did not differ between trials in *Study A* (0.60 ± 0.37 vs. 0.72 ± 0.53 mV, *P* = 0.106) or *Study B* (0.53 ± 0.39, 0.71 ± 0.42 and 0.60 ± 0.34 mV, *P* = 0.211).

Active motor threshold (aMT) was determined as the stimulator intensity that elicited a MEP of > 200 µV in three of five stimulations during a 10% MVC contraction. Stimulator intensity was increased in 5% steps from 35% of stimulator output until a consistent MEP amplitude >200 µV was found. Thereafter, stimulus intensity was reduced in 1% steps until the lowest intensity to elicit a MEP of >200 µV was found. aMT was not different

on any testing visit in *Study A* (40 ± 6 vs. 40 ± 7%, *P* = 0.746) or *Study B* (43 ± 9, 42 ± 8, and 43 ± 9%, *P* = 0.874). SICI was assessed with 10 paired and 10 single pulse stimulations delivered. Paired-pulse TMS consisted of a conditioning pulse at 70% of aMT and a test pulse at 120% aMT, with an interstimulus interval of 2 ms. All stimuli were delivered during a 10% contraction. This paradigm has previously been demonstrated to be the optimal configuration for eliciting SICI in the KE ([8]), and it has been used previously in our laboratory in male populations ([31]). Two sets of 10 stimuli were used, with a 10-s rest between contractions.

Blood Sampling and Hormone Analysis (Study B only)

Venous blood sampling was performed on the morning of each testing session. A 10-ml blood sample was drawn from an antecubital vein into a silica-coated tube by a trained phlebotomist and then left upright for 15 min to coagulate before centrifuging. Samples were centrifuged at 2,500 rpm for 10 min at room temperature (Allegra-X22R; Beckman Coulter, Sykesville, MD). Using a 500- to 1,000-µl pipette, the supernatant serum was separated into three aliquots (~1000 µl each) and stored at −80°C until estradiol and progesterone analyses were performed. Total concentrations of 17β-estradiol and progesterone were measured in duplicate using hormone-specific enzyme-linked immunoassay kits (Cayman Chemical, Ann Arbor, MI). All samples were analyzed using the ELISA technique with absorbance detection (wavelength 405 nm). The minimal estradiol and progesterone detection was 15 pg/ml and 7.5 pg/ml, respectively. To calculate 17β-estradiol and progesterone levels, a standard curve was plotted using eight standards against their absorbance. Using the mean absorbance from the duplicate of each sample, the concentration of the sample was interpolated directly from the standard curve. The coefficients of variation (CVs) for the ELISA kits, as provided by the manufacturer, were 8–12% for 17β-estradiol, and 5–8% for progesterone. In one instance, the CV of a duplicate sample exceeded the manufacturer's CV due to an excessively high (nonphysiological) reading in one well. Therefore, the lower of the two was used for data analysis. Participants' hormonal profiles were deemed "acceptable" when a peak in progesterone concentration was observed during the luteal phase (D21) and an increase in 17β-estradiol was observed from D2 to D14. If neither peak was observed, participants were deemed anovulatory and excluded from further analyses.

Data Analysis

Voluntary activation using motor nerve stimulation was determined using the ITT ([48]) by comparing the amplitude of the superimposed twitch (SIT) with the amplitude of the potentiated resting twitch ($Q_{tw.pot}$) using the following formula: VA_{MNS} (%) = (1 − [SIT ÷ $Q_{tw.pot}$]) × 100. VA using TMS was assessed during two sets of contractions at 100, 87.5, 75, 62.5, and 50% MVC ([19]). Single-pulse TMS was delivered during each contraction, and the linear regression between SIT amplitude and contraction intensity was extrapolated to the *y*-intercept to obtain an estimated resting twitch (ERT; [68]). To achieve significant linearity (*P* < 0.05), a total of 4 of 300 SITs across all trials in *Study A* were excluded (1.3%), which led to 4 regressions containing 9 data points rather than 10 (1 preexercise, 3 postexercise). In *Study B*, 6 of 870 SITs were excluded from all linear regressions (0.7%), meaning that there were 86 10-point regressions, 3 9-point regressions, and 1 8-point regression used to estimate resting twitches. Mean r^2 values for ERTs in *Study A* were 0.94 ± 0.04 preexercise vs. 0.94 ± 0.04 postexercise and in *Study B* were 0.92 ± 0.05 preexercise, and 0.89 ± 0.07 postexercise. The SIT during 100% MVC was compared with the ERT using the following formula: VA_{TMS} (%) = (1 − [SIT ÷ ERT]) × 100. SICI was quantified as the percentage ratio between the amplitude of conditioned MEPs to the amplitude of unconditioned MEPs. Corticospinal excitability was determined by expressing the mean MEP amplitude during the 10% MVC as a percentage of M_{max}. The rmsEMG was recorded during the middle 500-ms epoch of each 3-s contraction during the fatiguing task. rmsEMG was then expressed as a percentage of M_{max}. For the data presented as %TTF, the MVC, VA_{MNS}, and $Q_{tw.pot}$ for the nearest minute during the fatiguing protocols were taken, and the average rmsEMG for the nearest full set of contractions to the target percentage (i.e., 25, 50, or 75% TTF) was taken; for 0 and 100% TTF, the first and last complete sets were used. All data analysis was performed offline. In *Study B*, despite rigorous familiarization and verbal encouragement, one participant failed to maintain the intermittent contractions for the required 3 s during the fatiguing task, thus invalidating the TTF duration. Therefore, it was deemed appropriate to remove the participant's TTF duration and posttrial

neuromuscular assessment from further analysis (n = 14); however, baseline data were included for statistical analysis (n = 15).

Statistical Analysis

Data are presented as mean ± SD within the text and figures. Normal Gaussian distribution of data was confirmed using the Kolmogorov-Smirnov test. If a violation was detected, the data were logarithmically transformed. The α for all statistical tests was set at $P \leq 0.05$.

For *Study A*, between-session and pre- to postexercise differences were explored using two-way (2 × 2) repeated-measures ANOVAs; if assumptions of sphericity were violated, then the Greenhouse-Geisser correction was applied. If significant main or interaction effects were detected, Bonferroni-corrected post hoc tests were performed. For between-session test-retest reliability, multiple indexes were calculated [paired-samples *t*-tests, typical error, intraclass correlation coefficient ([2](#), [36](#))] between the two time points. Within-subjects variation was calculated as the standard deviation of the mean differences divided by the square root of 2 and termed typical error (TE) throughout the paper. Typical error was expressed as absolute raw values and as a percentage of the mean CV. Intraclass correlation coefficients ($ICC_{3,1}$) were calculated according to Bland and Altman ([5](#)). ICC values were defined as follows: <0.5 = poor, 0.5–0.75 = moderate, 0.75–0.9 = good, >0.9 = excellent ([45](#)). Due to the ceiling effect (i.e., all values grouped close to 100%) associated with VA_{MNS} and VA_{TMS}, the ICCs were not calculated ([16](#), [67](#)).

For *Study B*, one-way repeated-measures ANOVAs were run for all pre-exercise-dependent variables to assess MCP changes in neuromuscular function and hormone concentrations. Sphericity was assessed using Mauchly's test and, if necessary, was controlled using the Greenhouse-Geisser correction. Two-way repeated-measures ANOVAs were run using pre- and postexercise variables to obtain both fatigue and MCP × fatigue interaction effects. To explore potential differences in the fatigue profiles of neuromuscular and perceptual variables, two-way repeated-measures ANOVAs were run, including data points from baseline and 25, 50, 75, and 100% of TTF. Significant main and interaction effects were explored using Bonferroni-corrected tests.

RESULTS

Study A

Exercise performance and pre- to postexercise changes.
The TTF was not different between experimental visits (560 ± 275 vs. 603 ± 357 s, respectively, P = 0.314). When assessing exercise-induced changes in neuromuscular function, the two-way ANOVAs detected no between-trial differences in change scores (trial × time interactions: $P \geq 0.331$), therefore to assess the pre-to-post change, data from both visits were pooled. The MVC decreased pre- to postexercise (time effect: 507 ± 95 vs. 379 ± 85 N; $F_{1,14}$ = 136.66, P < 0.001, η^2 = 0.91). Similarly, indices of contractile function ($Q_{tw.pot}$ and ERT) decreased pre- to posttrial ($Q_{tw.pot}$: 169 ± 24 vs. 109 ± 21 N; $F_{1,14}$ = 92.61, P < 0.001, η^2 = 0.87; ERT: 120 ± 36 vs. 93 ± 28 N; $F_{1,14}$ = 19.07, P = 0.001, η^2 = 0.56). Indices of VA also decreased pre- to posttrial: VA_{MNS} (93.6 ± 3.2 vs. 85.1 ± 6.8%; $F_{1,14}$ = 36.60, P < 0.001, η^2 = 0.72) and VA_{TMS} (94.6 ± 3.1 vs. 83.1 ± 10.6%; $F_{1,14}$ = 20.82, P < 0.001, η^2 = 0.60). Corticospinal excitability (MEP/M_{max}) was not different pre- to postexercise (P = 0.057). There were no changes in SICI pre- to postexercise (80.8 ± 14.2 vs. 79.8 ± 13.9%, P = 0.667), whereas SP duration lengthened (189 ± 46 vs. 202 ± 50 ms, $F_{1,14}$ = 5.49, P = 0.034, η^2 = 0.28). Last, M_{max} was not different pre- to postexercise (3.02 ± 1.19 vs. 2.81 ± 1.01 mV, P = 0.362).

Reliability of neuromuscular measures.
Preexercise data from mechanical variables ([Table 2](#)) showed good (ERT and TTF) and excellent (MVC and $Q_{tw,pot}$) reliability. The TE and CV were also low for the majority of variables (CV ≤ 12.5%), except TTF (CV = 20.0%). Postexercise reliability ([Table 2](#)) was weaker but still interpreted as predominantly good ($Q_{tw,pot}$ and ERT) or excellent (MVC). These values were all poorer postexercise but remained relatively low (CV ≤ 14.9%). The relative reliability (ICCs) of the pre-to-post change was either moderate (MVC, ERT, and VA_{MNS}) or good ($Q_{tw,pot}$); however, there was a high degree of random error (CV range: 19.7–62.7%).

Table 2. Reliability data for mechanical variables pre- and postexercise in Study A							
Measure	*Visit 1*	*Visit 2*	*P*	Bias	TE	CV (%)	ICC (95% CI)
MVC, N							
Pre	502 ± 90	511 ± 103	0.314	−9	23	4.5	0.96 (0.89–0.98)
Post	375 ± 93	383 ± 81	0.356	−8	24	6.2	0.94 (0.82–0.98)
Δ	−128 ± 43	−128 ± 51	0.972	0	30	23.9	0.62 (0.18–0.85)
$Q_{tw.pot}$, N							
Pre	168 ± 27	170 ± 22	0.589	−2	9	5.0	0.90 (0.72–0.96)
Post	110 ± 22	110 ± 21	0.942	0	11	10.4	0.75 (0.40–0.91)
Δ	−58 ± 29	−61 ± 21	0.643	−2	12	19.7	0.81 (0.53–0.93)
ERT, N							
Pre	121 ± 38	118 ± 34	0.689	3	15	12.5	0.85 (0.62–0.95)
Post	94 ± 30	91 ± 27	0.605	3	14	14.9	0.79 (0.48–0.92)
Δ	−27 ± 25	−27 ± 28	0.943	0	17	62.7	0.63 (0.20–0.86)
VA_{TMS}, %							
Pre	94.3 ± 3.3	94.8 ± 2.9	0.679	−0.5	2.8	3.0	
Post	82.3 ± 11.1	83.9 ± 10.4	0.406	−1.6	5.1	6.1	
Δ	−12.0 ± 11.2	−10.9 ± 9.6	0.573	1.1	5.2	45.4	0.78 (0.46–0.92)
VA_{MNS}, %							
Pre	93.6 ± 3.0	93.7 ± 3.2	0.834	−0.1	1.6	1.7	
Post	84.5 ± 7.2	85.8 ± 6.7	0.942	−1.3	3.6	4.2	

		−9.1 ± 6.0	−7.9 ± 6.1	0.390	1.2	3.7	43.2	0.66 (0.24–0.87)
Δ								
TTF, s		560 ± 275	603 ± 357	0.338	−43	117	20.0	0.88 (0.69–0.96)

Values are means ± SD. Pre-to-Post change (Δ) is presented when a significant ($P < 0.05$) change was observed. CV, coefficient of variation; ICC, intraclass correlation coefficient; MVC, maximum voluntary contraction; $Q_{tw.pot}$, potentiated quadriceps twitch; ERT, estimated resting twitch; VA_{TMS}, voluntary activation assessed with transcranial magnetic stimulation; VA_{MNS}, voluntary activation assessed with motor nerve stimulation; TE, typical error; TTF, time to task failure.

Surface EMG variables (Table 3) showed moderate (MEP/M_{max} and SP) or good (SICI and M_{max}) reliability preexercise but with larger test-retest CVs than mechanical variables (CV range: 9.2–30.1%). Postexercise reliability was similar to preexercise for most variables, with ICCs either moderate (MEP/M_{max} and SP) or good (M_{max}) and comparable CVs (range: 13.0–31.0%). Despite this, the postexercise reliability of SICI was poor (ICC = 0.42), which was further supported by a significant bias between *visits 1* and *2* (−9.1%, $P = 0.031$). When the pre-to-post change was significant for a variable, i.e., SP, the relative reliability of change value was deemed poor (ICC = 0.44), with a high degree of random error (CV = 155.1%).

Table 3. Reliability values for electromyographical data pre- and postexercise							
Measure	*Visit 1*	*Visit 2*	*P*	**Bias**	**TE**	**CV, %**	**ICC (95% CI)**
MEP/M_{max}, %							
Pre	22.4 ± 12.0	19.8 ± 10.5	0.291	2.6	6.4	30.1	0.71 (0.34–0.89)
Post	17.8 ± 9.0	16.9 ± 10.1	0.677	0.9	5.4	31.0	0.72 (0.34–0.90)
Δ							
SICI, %							
Pre	78.7 ± 15.0	82.9 ± 13.5	0.148	−4.2	7.4	9.2	0.75 (0.42–0.91)
Post	75.3 ± 13.3	84.3 ± 13.3	0.031	−9.1	10.4	13.0	0.42 (0.00–0.75)
Δ							
M_{max}, mV							
Pre	2.96 ± 1.13	3.08 ± 1.28	0.507	−0.12	0.48	15.9	0.86 (0.64–0.92)
Post	2.74 ± 1.01	2.88 ± 1.03	0.466	−0.14	0.50	17.8	0.79 (0.47–0.92)
Δ							
SP, ms							
Pre	187 ± 45	190 ± 50	0.791	−3	31	16.4	0.60 (0.24–0.82)

Post	201 ± 56	202 ± 46	0.947	−8	37	19.2	0.63 (0.19–0.86)
Δ	14 ± 29	12 ± 23	0.815	2	20	155.1	0.44 (0.00–0.77)

Values are means ± SD. Pre-to-Post change (Δ) is presented when a significant ($P < 0.05$) change was observed.CV, coefficient of variation; ICC, intraclass correlation coefficient; MEP, motor evoked potential,; MVC, maximum voluntary contraction; SICI, short-interval cortical inhibition; M_{max}, maximum compound action potential; TE, typical error.

Study B
Hormonal profiles.

Thirteen of 15 participants presented a regular hormonal profile (Table 4). Two participants had no increase in progesterone on D21; given the hypothesis that changing hormone concentrations would modulate neuromuscular function, and these participants did not exhibit any change in hormone concentrations, they were excluded from further statistical analyses. The repeated-measures ANOVAs showed an effect of MCP on 17β-estradiol ($F_{1.4,19.5} = 3.55$, $P = 0.040$, $\eta_p^2 = 0.18$) and progesterone concentration ($F_{= 1.0,14.1} = 8.35$, $P = 0.012$, $\eta_p^2 = 0.37$). Post hoc tests revealed that 17β-estradiol concentrations were greater on D14 than on D2 ($P = 0.033$) and greater on D21 than D2 ($P = 0.029$). Progesterone was greater on D21 than D2 and D14 ($P = 0.011$, and 0.012, respectively).

Table 4. Group average concentrations for 17β-estradiol and progesterone across the 3 tested phases of the menstrual cycle			
	Day 2	**Day 14**	**Day 21**
17β-Estradiol, pg/ml	248 ± 129	328 ± 160*	341 ± 186*
Progesterone, ng/ml	1.27 ± 0.50	1.38 ± 0.69	4.41 ± 4.60*#
E:P ratio	0.20 ± 0.13	0.28 ± 0.18	0.12 ± 0.10*#

Values are means ± SD. E:P, estrogen-to-progesterone; D, day of cycle.

*greater than D2;

#greater than D14.

Baseline neuromuscular function.
MVC force was unaffected by MCP (Fig. 1A, $F_{1.4,16.8} = 0.15$, $P = 0.790$, $\eta_p^2 = 0.01$). Potentiated twitch force was also unchanged (Fig. 1B; $F_{2,24} = 0.25$, $P = 0.782$, $\eta_p^2 = 0.02$); however, the SIT elicited by MNS was affected by MCP ($F_{2,28} = 3.69$, $P = 0.040$, $\eta_p^2 = 0.24$), with greater SITs on D14 compared with D2 (mean difference: 2 N, $P = 0.031$). The reduced SIT on D14 meant that VA_{MNS} was affected by MCP (Fig. 1C; $F_{2,28} = 9.23$, $P = 0.001$, $\eta_p^2 = 0.44$), with post hoc tests showing greater VA_{MNS} on D14 than on D2 (mean difference: 1.9%, $P = 0.007$); however, there was no difference between D14 and D21 (mean difference: 1.0%, $P = 0.059$). VA_{TMS} was also affected by MCP (Fig. 1D; $F_{2,28} = 5.89$, $P = 0.008$, $\eta_p^2 = 0.33$), with greater values on D14 than on D21 (mean difference: 3.0%, $P = 0.016$); however, D14 and D2 were not different (mean difference: 2.5%, $P = 0.080$).

Despite the change in VA_{TMS}, neither of its constituent parts were altered by MCP: ERT ($F_{1.3,15.3} = 0.25$, $P = 0.784$, $\eta_p^2 = 0.02$) and SIT elicited by TMS ($F_{1.3,15.3} = 2.17$, $P = 0.136$, $\eta_p^2 = 0.15$).

Fig. 1. Baseline neuromuscular measures across the 3 time points. *A*: maximum voluntary contraction (MVC). *B*: potentiated twitch force ($Q_{tw.pot}$). *C*: voluntary activation assessed with motor nerve stimulation (VA_{MNS}). *D*: VA assessed with transcranial magnetic stimulation (VA_{TMS}). *E*: superimposed MVS-evoked twitch during a maximum voluntary contraction (SIT_{MNS}). *F*: superimposed transcranial magnetic stimulation (TMS)-evoked twitch during a MVC (SIT_{TMS}). Individual data are shown with mean data overlaid as filled symbols and connecting line.

As shown in Table 3, M_{max} was unaffected by MCP ($F_{2,28} = 0.24$, $P = 0.786$, $\eta_p^2 = 0.02$), nor was normalized MEP amplitude (Fig. 2A; $F_{2,28} = 2.24$, $P = 0.129$, $\eta_p^2 = 0.16$). However, SICI was affected (Table 5 and Fig. 2B; $F_{1.4,16.8} = 13.52$, $P < 0.001$, $\eta_p^2 = 0.53$), with post hoc tests showing greater inhibition on D21 than on D2 (mean difference: −10%, $P = 0.048$) and D14 (mean difference: −14%, $P = 0.001$). The prestimulus normalized rmsEMG activity was not different between MCPs (D2, 1.16 ± 0.43; D14, 1.07 ± 0.53; D21, $1.20 \pm 0.64\%$ M_{max}, $F_{2,28} = 0.31$, $P = 0.736$, $\eta_p^2 = 0.025$), and neither was the SP (Fig. 2C and Table 5; $F_{2,28} = 0.53$, $P = 0.594$, $\eta_p^2 = 0.04$).

Fig. 2. Transcranial magnetic stimulation evoked responses across the 3 testing time points. *A*: corticospinal excitability: motor evoked potential (MEP)/maximal muscle action potential (M_{Max}). *B*: short-interval cortical inhibition (SICI). *C*: transcranial magnetic stimulation-evoked silent period. Individual data are shown with mean data overlaid as filled symbols and connecting line.

Table 5. Variables assessed throughout the pre- and post-exercise testing battery across the menstrual cycle

	Day 2			Day 14			Day 21			MCP Effect	Pre-to-Post Exercise	MCP x Exercise
	Pre	Post	Δ	Pre	Post	Δ	Pre	Post	Δ	1 × 3 ANOVA	2 × 3 ANOVA	2 × 3 ANOVA
MVC, N	457 ± 79	344 ± 59	−25%	454 ± 78	337 ± 67	−26%	460 ± 87	355 ± 93	−24%	0.790	**<0.001**	0.236
SIT_M NS, N	9 ± 5#	11 ± 7		7 ± 4	10 ± 8		8 ± 4	11 ± 6		**0.040**	**0.069**	0.452

$Q_{tw.pot}$ N	148 ± 20	95 ± 24	−36%	150 ± 20	91 ± 22	−39%	151 ± 23	94 ± 26	−38%	0.782	**<0.001**	0.634
VA_{MNs}, %	93.4 ± 2.8	88.4 ± 8.8	−6%	95.3 ± 1.9*	87.9 ± 6.9	−8%	94.3 ± 2.2	88.0 ± 5.6	−7%	**0.001**	**0.002**	0.303
SIT_{TMs}, N	6 ± 2	10 ± 8	67%	5 ± 3	9 ± 7	80%	7 ± 6	10 ± 9	43%	0.136	**0.028**	0.292
ERT, N	94 ± 43,	74 ± 37	−35%	96 ± 39	64 ± 60	−40%	93 ± 43	70 ± 36	−35%	0.784	**0.001**	0.128
VA_{TMs}, %	93.2 ± 2.8	87.5 ± 8.5	−6%	95.7 ± 2.4†	84.3 ± 9.4	−12%	92.6 ± 3.2	86.7 ± 9.7	−7%	**0.008**	**0.003**	**0.049**
MEP/M_{max}, %	17 ± 5	17 ± 9		22 ± 7	18 ± 9		18 ± 10	15 ± 8		0.129	0.278	0.485
SICI, %	77 ± 11*	84 ± 14		82 ± 10*	74 ± 22		67 ± 12	75 ± 19		**0.001**	0.578	**0.028**
SP, ms	160 ± 42	176 ± 49	12%	173 ± 70	176 ± 54	2%	174 ± 48	176 ± 49	3%	0.594	**0.010**	0.360
M_{max}, mV	4.05 ± 2.19	3.93 ± 2.27		4.39 ± 1.88	4.06 ± 2.12		4.30 ± 2.50	3.80 ± 2.28		0.786	0.087	0.436
TTF, s	519 ± 164			571 ± 179			706 ± 262*			**0.030**		

Values are means ± SD. *P* values from the baseline ANOVA (1 × 3 repeated measures), and the pre- to postexercise ANOVA (2 × 3 repeated measures) are reported. When a significant effect of exercise was found, the Δ in a variable from pre- to postexercise was reported. Day, day of cycle; MVC, maximum voluntary contraction; SIT_{MNs}, superimposed twitch elicited by motor nerve stimulation; $Q_{tw.pot}$, potentiated quadriceps twitch; VA_{MNs}, voluntary activation assessed with motor nerve stimulation; SIT_{TMs}, superimposed twitch elicited by transcranial magnetic stimulation (TMS); ERT, estimated resting twitch; VA_{TMs}, voluntary activation assessed with TMS; MEP/M_{max}, corticospinal excitability; SICI, short-interval cortical inhibition; SP, TMS evoked silent period; M_{max}, maximum compound muscle action potential; TTF, time to task failure.

Fatigability.
Time to task failure during the intermittent, isometric, fatiguing task was significantly affected by MCP (Fig. 3, $F_{1.4, 14.8}$ = 6.89, *P* = 0.030, η_p^2 = 0.32), with post hoc tests showing greater TTF on D21 than on D2 (mean difference: 187 s, *P* = 0.025). However, there was no difference between D21 and D14 (mean difference: 135 s, *P* = 0.103) or D2 and D14 (*P* = 0.594). The two-way ANOVA (MCP × time) time effect showed that MVC decreased pre- to postexercise ($F_{1,11}$ = 80.056, *P* < 0.001, η_p^2 = 0.88), as did $Q_{tw.pot}$ ($F_{1,11}$ = 123.53, *P* < 0.001, η_p^2 = 0.92), VA_{MNs} ($F_{1,11}$ = 15.219, *P* = 0.002, η_p^2 = 0.58), and VA_{TMs} ($F_{1,11}$ = 13.99, *P* = 0.003, η_p^2 = 0.56). SP also increased pre- to postexercise ($F_{1,11}$ = 9.68, *P* = 0.010, η_p^2 = 0.468). The MCP × time interaction effects for the aforementioned variables that changed pre- to postexercise indicated no difference between MCPs (all *P* ≥ 0.128). The only exception to this was VA_{TMs} ($F_{2,22}$ = 3.48, *P* = 0.049, η_p^2 = 0.24); however, post hoc tests revealed that the differences were only apparent preexercise (as indicated above) and not postexercise (*P* ≥ 0.670). Despite no time effect (*P* = 0.578), SICI displayed a MCP × time interaction effect ($F_{1.4, 15.0}$ = 5.26, *P* = 0.028, η_p^2 = 0.32); however, the only differences were evident preexercise (as indicated above), with no post-exercise difference (*P* ≥ 0.247).

Fig. 3. Time to task failure during the submaximal intermittent isometric fatiguing task at the 3 testing time points. Individual data are shown with mean data overlaid as filled symbols and connecting line.

All variables measured during the fatiguing tasks ([Fig. 4](#)) demonstrated time effects ($P \leq 0.024$); however, only some (MVC, $Q_{tw.pot}$, and VA_{MNS}) demonstrated an absence of MCP × time interaction effects ($P \geq 0.205$). MVC ([Fig. 4A](#)) decreased progressively from baseline to 75% TTF (all intervals $P \leq 0.001$); however, between 75 and 100% TTF, no further decrease was observed ($P = 0.776$). A similar pattern was observed with $Q_{tw.pot}$ ([Fig. 4B](#)), with decreases exhibited until 50% TTF (both intervals $P \leq 0.009$); however, between 50 and 100% TTF, $Q_{tw.pot}$ did not further decrease ($P \geq 0.593$). VA_{MNS} ([Fig. 4C](#)) demonstrated the inverse time course, with no change from 0 to 50% TTF ($P \geq 0.345$) and then a progressive decrease from 50 to 100% TTF ($P \leq 0.034$). rmsEMG ([Fig. 4D](#)) and RPE ([Fig. 4E](#)) exhibited phase × time interaction effects ($P \leq 0.032$). RPE increased progressively throughout all trials ($P \leq 0.008$). However, at 25% TTF, RPE was greater on D21 than on D14 (+2, $P = 0.006$); at 50% TTF, D21 was greater than D2 (+2, $P < 0.001$); and at 75% TTF, D21 was greater than D2 (+1, $P = 0.005$). The only significant increase in rmsEMG was between 25 and 50% TTF ($P = 0.003$), and despite the phase × time interaction effect, no post hoc differences between phases were apparent ($P \geq 0.205$).

Fig. 4. Neuromuscular variables assessed at 25, 50, 75, and 100% time to task failure (TTF) throughout the fatiguing tasks in each menstrual cycle phase MCP. *A*: maximum voluntary contraction (MVC). *B*: potentiated quadriceps twitch ($Q_{tw.pot}$). *C*: voluntary activation assessed with motor nerve stimulation (VA_{MNS}). *D*: root mean squared EMG (rmsEMG). *E*: rating of perceived exertion (RPE). Data are means with standard deviation shown in *A–D* for the final point. Data are displayed as %baseline, although statistical analyses were performed on absolute data. Statistical differences ($P < 0.05$) are depicted by letters: [a]between baseline and 25% TTF; [b]between 25 and 50% TTF; [c]between 50 and 75% TTF; [d]between 75 and 100% TTF; *between D21 and D14; #between D21 and D2. D2, white circles; D14, gray circles; D21, black circles.

DISCUSSION

The present investigation aimed to assess the influence of modulations in female sex hormones across the eumenorrheic menstrual cycle on neuromuscular function and fatigability. The data from *Study A* established repeatability of the measures in a hormonally constant female population (mOCP users). Subsequently, *Study B* showed that in eumenorrheic women the hormone-induced changes in neuromuscular function and fatigability across the menstrual cycle were greater than the associated error from hormonally constant women in *Study A*. Although one index of neuromuscular function (MVC) did not change, modulations in CNS control of muscle contraction were observed. Specifically, VA was greatest on D14, which was concurrent with an increase in the concentration of estrogen. Additionally, parallel to an increase in progesterone, SICI was greatest on D21. Time to task failure during the open-ended, intermittent, isometric protocol was greatest on D21 of the cycle. Collectively, the present data suggest that neuromuscular function and fatigability are modulated by the eumenorrheic menstrual cycle.

Maximum Strength and VA Across the Menstrual Cycle

There was no effect of MCP on MVC force. As mentioned, previous data regarding maximum voluntary strength across the menstrual cycle is equivocal. In agreement with the present study, multiple studies have shown no effect ([24](#), [40](#), [46](#)); however, several studies have shown that strength peaks midcycle ([49](#), [53](#), [64](#)). Previously, discrepancies such as the time of day ([4](#)) or variability in menstrual cycle duration, as well as the chosen days of the menstrual cycle for testing ([27](#)), have been used as explanatory reasons for this discrepancy. The present study controlled these factors within *Study B* by testing at the same time of day and confirming that participants were in the correct phase by serum hormone analysis, yet no effect of MCP was observed.

Interestingly, *Study B* demonstrated changes in VA (assessed by both MNS and TMS) despite no change in MVC. VA_{MNS} peaked on D14, and VA_{TMS} was greater on D14 compared with D21 (see [Fig. 1](#)). As $Q_{tw.pot}$ and ERT were not affected by MCP, these changes in VA were mediated by a decreased SIT amplitude on D14 in response to both motor nerve and motor cortical stimulation. This could indicate that there was a decrease in the capacity of the CNS to elicit extra force in response to stimulation. The TMS- and MNS-evoked SITs represent the extra force from motor units that the CNS is not able to voluntarily recruit or discharge at a sufficient rate ([68](#)). As acknowledged by Todd et al. ([68](#)), a change in SIT force could be caused by changes in the CNS altering activation of the motoneuron; therefore, changes within the motor cortex could provide an explanation for the change in VA. An alternative explanation could be the magnitude of the respective measurement errors of these variables. In *Study A*, when hormones were controlled, the CVs of VA_{MNS} (1.7%) and VA_{TMS} (3.0%) are lower than the TE for MVC (5.0%). Although changes seen in the present data set (i.e., the 1.8% increase in VA_{MNS} between D2 and D14 or the 3.1% decrease in VA_{TMS} between D14 and D21) were similar to typical error, it could be the case that the increase in VA was not large enough to elicit a detectable increase in MVC due to its larger TE. Previous studies that have shown VA_{MNS} not to change have used the central activation ratio ([40](#), [46](#)), which is less sensitive to change than the ITT ([50](#)). It is likely, therefore, that the magnitude of menstrual cycle effect on VA_{MNS} and VA_{TMS} is marginally greater than the random error associated with the techniques used to assess it; thus, based on current evidence, the true effect is unclear. Also of note is the MCP × time interaction effect for VA_{TMS}, which would indicate that the magnitude of change from pre- to postexercise was different between MCPs. However, this appears to have been driven by the increased VA_{TMS} preexercise on D14, as there were no differences in postexercise values. Therefore, it is unlikely that participants experienced a greater degree of CNS adjustment following exercise during the late-follicular phase (D14).

Corticospinal and Intracortical Function Across the Menstrual Cycle

As mentioned, the increase in both measurements of VA on D14 (VA_{MNS} and VA_{TMS}) could represent changes in supraspinal properties altering synaptic drive to the motoneuron pool across the menstrual cycle ([51](#)). To investigate the state of the corticospinal tract and motor cortex, the present study employed single- and paired-pulse TMS. No menstrual cycle effect was observed on corticospinal excitability; however, intracortical inhibition was increased on D21. Single-pulse MEPs in the resting first dorsal interosseous muscle have previously been shown not to be affected by estrogen concentrations [day 1 vs. day 14 of the menstrual cycle ([39](#))], and the present study extends this conclusion to the active knee extensors while demonstrating that the increase of progesterone concentrations on D21 is not concurrent with changes in corticospinal excitability. When paired-pulse responses are considered, however, the increase in progesterone concentrations was concomitant with an ~14% increase in SICI, which when considered with previous evidence ([37](#), [59](#)) was likely through potentiation of $GABA_A$ inhibition. Indeed, GABA agonist pharmacological interventions (e.g., baclofen and gabapentin) have shown similar changes ([74](#)). The difference between D14 and D21 demonstrated in *Study B* (14%) was double the measurement error of SICI observed in *Study A* (7%); however, there was no difference between D2 and D14 (difference = 4%). Interestingly, SICI followed a similar pattern to the estrogen-to-progesterone (E/P) ratio (see [Table 4](#)), with the only significant change demonstrated on D21 concurrent to a decrease in the E/P ratio. Furthermore, the MCP × time interaction effect for SICI in *Study B* would suggest that intracortical inhibition is differentially modulated by exercise throughout the menstrual cycle. Although this is a concept that has been postulated before ([23](#)), and the present data appear to show this phenomenon, the interaction should be

treated with caution, as the postexercise reliability of SICI in *Study A* was poor. A significant bias was observed (P = 0.031), with a poor ICC value (0.42); thus, a conclusion regarding MCP-specific changes in intracortical inhibition following exercise cannot be confidently made using the present data.

The TMS SP, thought to partly reflect $GABA_B$ inhibitory mechanisms ([14]), was not affected by MCP, supporting previous data recorded in the FDI muscle ([33]). However, the conclusion that the menstrual cycle affects only $GABA_A$ neurotransmission cannot be made with the current data, as Yacyshyn et al. ([73]) showed that the SP has a large spinal contribution. Additionally, glutamatergic intracortical facilitation (ICF) was not measured in the present study, but it has previously been shown to be affected by the menstrual cycle, with augmented ICF demonstrated midcycle ([56], [57]). Although the causal link between intracortical function and VA is underresearched, it is possible that the adjustments of intracortical circuitry altered the capacity of TMS and MNS to evoke a SIT. For instance, if intracortical excitability was greatest on D14, there may have been a "ceiling effect," meaning the stimulations were not able to induce additional excitation in the motor cortex, thus innervating fewer additive motor units during MVCs and evoking a smaller SIT, and the contrary occurring on D21, when inhibition was greatest. The modulation of neurotransmitters has previously shown to affect VA, with pharmacological increases in norepinephrine ([44]) and serotonin ([42]) resulting in a ~1–2% increase in VA. Indeed the effects of serotonin have been shown to be augmented by estrogen ([3]) and inhibited by progesterone ([34]). Therefore, it is possible that the modulation of inhibitory and facilitatory intracortical circuitry across the menstrual cycle might collectively contribute to the changes in VA_{MNS} and VA_{TMS}.

Fatigability Across the Menstrual Cycle

Fatigability, as measured by the TTF of the open-ended fatiguing protocol, was lowest on D21 (i.e., greatest TTF), thus supporting the findings of Sarwar et al. ([53]), who showed that fatigue index was lowest in the luteal phase during a 3-min intermittent involuntary contraction protocol. The present data, however, contradict Janse de Jonge et al. ([40]), who showed no effect of MCP during voluntary or electrically evoked fatiguing protocols performed with the KE. The differences between tasks could explain these discrepancies. The voluntary task used by Janse de Jonge et al. ([44]) involved both dynamic knee extension and flexion rather than a single muscle group. This anisometric, multi-muscle group exercise likely elicits a different pattern of sensory afferent feedback ([30]) and was not open-ended like the present study, which could explain the discrepancies in fatigability. The same reasons might also apply to why the findings of DiBrezzo et al. ([21]) are inconsistent with those of the present study, who similarly demonstrated no menstrual cycle effect on fatigue during a set amount of dynamic contractions. Thus, the task employed in the present study likely permitted a greater degree of fatigue to develop, allowing the aforementioned MCP differences to be discerned.

As widely acknowledged, fatigability has both physiological and perceptual components that interact to determine exercise tolerance ([26], [66]). The fatiguing task in the present study involved high-intensity (60% MVC), intermittent isometric contractions, which were assumed to be far greater than the critical torque [~30% MVC ([12])] and were limited by decrements in neuromuscular adjustments ([1], [11]). With no MCP × time interaction effects displayed for neuromuscular variables (MVC, $Q_{tw.pot}$, and VA), the degree of pre- to postexercise adjustment was not different between menstrual cycle phases. Accordingly, one hypothesis for why TTF was longer on D21 could be the influence of neurotransmitter systems on perceptions of fatigue. The present study measured GABAergic inhibition and demonstrated a large increase in SICI on D21 ([Fig. 2*B*]), and it has previously been shown that GABA can have antinociceptive properties ([25]) acting as an analgesic ([41]). Indeed, it has recently been postulated that "luteal analgesia" occurs in eumenorrheic women when progesterone is elevated, where the affective response to nociceptive pain is reduced due to alterations in functional connectivity in the emotional regulation network ([69]). Thus, it could be possible that the analgesic effects of enhanced GABAergic neurotransmission permitted participants to continue exercising for a longer period due to a lower perception of pain. However, more evidence is needed to explore the effects of GABAergic inhibition on exercise-induced fatigue.

Further Considerations

In *StudyB* it would appear that there was substantial between-subject variation in neuromuscular function and the changes across the menstrual cycle (Figs. 1–3). Potential explanations for this could be the large standard deviations in hormone concentrations at each time point (Table 4), which has been reported in previous investigations (55). Additionally, interindividual differences in hormone receptor numbers and sensitivity could contribute to the variation in changes across the menstrual cycle. In muscle tissue (22), expression of sex hormone receptors is altered by changing hormonal environments, which could conceivably occur in neuronal tissues such as the motor cortex; however, the present data cannot answer this research question.

While serum hormones were quantified for the eumenorrheic women in *Study B*, the mOCP users' serum hormone concentrations were not quantified in *Study A*. These data would have provided useful information about the measurement error of the sample; however, individual "meaningful" changes might differ between participants to achieve ovulation.

Conclusion

The present investigation demonstrated that, when neuroactive hormones are constant, women demonstrate stable neuromuscular function (*Study A*). In contrast, when eumenorrheic women were tested at three distinct phases of the menstrual cycle (*Study B*), the changing hormonal environment coincided with large changes in CNS function, which affected aspects of motor performance. Specifically, estrogen had neuroexcitatory effects that were associated with an increase in VA on D14, whereas progesterone's neuroinhibitory effects were concurrent with an increased intracortical inhibition and decreased VA. Additionally, fatigability was modulated by MCP, with the greatest TTF seen on D21, concurrent with an increase in progesterone. Thus, the menstrual cycle elicits changes in neuromuscular function and fatigability in locomotor muscle of eumenorrheic women.

References

1. Amann M. Central and peripheral fatigue: interaction during cycling exercise in humans. Med Sci Sports Exerc 43: 2039–2045, 2011. doi:10.1249/MSS.0b013e31821f59ab.

2. Atkinson G, Nevill AM. Statistical methods for assessing measurement error (reliability) in variables relevant to sports medicine. Sports Med 26: 217–238, 1998. doi:10.2165/00007256-199826040-00002.

3. Bethea CL, Lu NZ, Gundlah C, Streicher JM. Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol 23: 41–100, 2002. doi:10.1006/frne.2001.0225.

4. Birch K, Reilly T. The diurnal rhythm in isometric muscular performance differs with eumenorrheic menstrual cycle phase. Chronobiol Int 19: 731–742, 2002. doi:10.1081/CBI-120006083.

5. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 327: 307–310, 1986. doi:10.1016/S0140-6736(86)90837-8.

6. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14: 377–381, 1982. doi:10.1249/00005768-198205000-00012.

7. Brouwer B, Ashby P. Corticospinal projections to upper and lower limb spinal motoneurons in man. Electroencephalogr Clin Neurophysiol 76: 509–519, 1990. doi:10.1016/0013-4694(90)90002-2.

8. Brownstein CG, Ansdell P, Škarabot J, Howatson G, Goodall S, Thomas K. An optimal protocol for measurement of corticospinal excitability, short intracortical inhibition and intracortical facilitation in the rectus femoris. J Neurol Sci 394: 45–56, 2018. doi:10.1016/j.jns.2018.09.001.

9. Brownstein CG, Dent JP, Parker P, Hicks KM, Howatson G, Goodall S, Thomas K. Etiology and recovery of neuromuscular fatigue following competitive soccer match-play. Front Physiol 8: 831, 2017. doi:10.3389/fphys.2017.00831.

10. Bryant AL, Clark RA, Bartold S, Murphy A, Bennell KL, Hohmann E, Marshall-Gradisnik S, Payne C, Crossley KM. Effects of estrogen on the mechanical behavior of the human Achilles tendon in vivo. J Appl Physiol (1985) 105: 1035–1043, 2008. doi:10.1152/japplphysiol.01281.2007.

11. Burnley M, Vanhatalo A, Fulford J, Jones AM. Similar metabolic perturbations during all-out and constant force exhaustive exercise in humans: a (31)P magnetic resonance spectroscopy study. Exp Physiol 95: 798–807, 2010. doi:10.1113/expphysiol.2010.052688.

12. Burnley M, Vanhatalo A, Jones AM. Distinct profiles of neuromuscular fatigue during muscle contractions below and above the critical torque in humans. J Appl Physiol (1985) 113: 215–223, 2012. doi:10.1152/japplphysiol.00022.2012.

13. Carroll TJ, Taylor JL, Gandevia SC. Recovery of central and peripheral neuromuscular fatigue after exercise. J Appl Physiol (1985) 122: 1068–1076, 2017. doi:10.1152/japplphysiol.00775.2016.

14. Chen R, Lozano AM, Ashby P. Mechanism of the silent period following transcranial magnetic stimulation. Evidence from epidural recordings. Exp Brain Res 128: 539–542, 1999. doi:10.1007/s002210050878.

15. Chen R, Tam A, Bütefisch C, Corwell B, Ziemann U, Rothwell JC, Cohen LG. Intracortical inhibition and facilitation in different representations of the human motor cortex. J Neurophysiol 80: 2870–2881, 1998. doi:10.1152/jn.1998.80.6.2870.

16. Clark BC, Cook SB, Ploutz-Snyder LL. Reliability of techniques to assess human neuromuscular function in vivo. J Electromyogr Kinesiol 17: 90–101, 2007. doi:10.1016/j.jelekin.2005.11.008.

17. Clarkson AN, Huang BS, Macisaac SE, Mody I, Carmichael ST. Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke. Nature 468: 305–309, 2010. doi:10.1038/nature09511.

18. Dekerle J, Ansdell P, Schäfer L, Greenhouse-Tucknott A, Wrightson J. Methodological issues with the assessment of voluntary activation using transcranial magnetic stimulation in the knee extensors. Eur J Appl Physiol 119: 991–1005, 2019. doi:10.1007/s00421-019-04089-7.

19. Dekerle J, Greenhouse-Tucknott A, Wrightson J, Schäfer L, Ansdell P. Improving the measurement of TMS-assessed voluntary activation in the knee extensors (Online). https://osf.io/45fsg. [2 August 2018].

20. Dibrezzo R, Fort IL, Brown B. Dynamic strength and work variations during three stages of the menstrual cycle. J Orthop Sports Phys Ther 10: 113–116, 1988. doi:10.2519/jospt.1988.10.4.113.

21. DiBrezzo R, Fort IL, Brown B. Relationships among strength, endurance, weight and body fat during three phases of the menstrual cycle. J Sports Med Phys Fitness 31: 89–94, 1991.

22. Ekenros L, Papoutsi Z, Fridén C, Dahlman Wright K, Lindén Hirschberg A. Expression of sex steroid hormone receptors in human skeletal muscle during the menstrual cycle. Acta Physiol (Oxf) 219: 486–493, 2017. doi:10.1111/apha.12757.

23. El-Sayes J, Harasym D, Turco CV, Locke MB, Nelson AJ. Exercise-induced neuroplasticity: a mechanistic model and prospects for promoting plasticity. Neuroscientist 25: 65–85, 2019. doi:10.1177/1073858418771538.

24. Elliott KJ, Cable NT, Reilly T, Diver MJ. Effect of menstrual cycle phase on the concentration of bioavailable 17-β oestradiol and testosterone and muscle strength. Clin Sci (Lond) 105: 663–669, 2003. doi:10.1042/CS20020360.

25. Enna SJ, McCarson KE. The role of GABA in the mediation and perception of pain. Adv Pharmacol 54: 1–27, 2006. doi:10.1016/S1054-3589(06)54001-3.

26. Enoka RM, Duchateau J. Translating fatigue to human performance. Med Sci Sports Exerc 48: 2228–2238, 2016. doi:10.1249/MSS.0000000000000929.

27. Fehring RJ, Schneider M, Raviele K. Variability in the phases of the menstrual cycle. J Obstet Gynecol Neonatal Nurs 35: 376–384, 2006. doi:10.1111/j.1552-6909.2006.00051.x.

28. Frye CA. An overview of oral contraceptives: mechanism of action and clinical use. Neurology 66, Suppl 3: S29–S36, 2006. doi:10.1212/WNL.66.66_suppl_3.S29.

29. Furlan L, Sterr A. The applicability of standard error of measurement and minimal detectable change to motor learning research—a behavioral study. Front Hum Neurosci 12: 95, 2018. doi:10.3389/fnhum.2018.00095.

30. Gandevia SC. Spinal and supraspinal factors in human muscle fatigue. Physiol Rev 81: 1725–1789, 2001. doi:10.1152/physrev.2001.81.4.1725.

31. Goodall S, Howatson G, Thomas K. Modulation of specific inhibitory networks in fatigued locomotor muscles of healthy males. Exp Brain Res 236: 463–473, 2018. doi:10.1007/s00221-017-5142-x.

32. Gruet M, Temesi J, Rupp T, Levy P, Verges S, Millet GY. Dynamics of corticospinal changes during and after high-intensity quadriceps exercise. Exp Physiol 99: 1053–1064, 2014. doi:10.1113/expphysiol.2014.078840.

33. Hausmann M, Tegenthoff M, Sänger J, Janssen F, Güntürkün O, Schwenkreis P. Transcallosal inhibition across the menstrual cycle: a TMS study. Clin Neurophysiol 117: 26–32, 2006. doi:10.1016/j.clinph.2005.08.022.

34. Henderson JA, Bethea CL. Differential effects of ovarian steroids and raloxifene on serotonin 1A and 2C receptor protein expression in macaques. Endocrine 33: 285–293, 2008. doi:10.1007/s12020-008-9087-5.

35. Hermens HJ, Freriks B, Disselhorst-Klug C, Rau G. Development of recommendations for SEMG sensors and sensor placement procedures. J Electromyogr Kinesiol 10: 361–374, 2000. doi:10.1016/S1050-6411(00)00027-4.

36. Hopkins WG. Measures of reliability in sports medicine and science. Sports Med 30: 1–15, 2000. doi:10.2165/00007256-200030010-00001.

37. Hsu F-C, Smith SS. Progesterone withdrawal reduces paired-pulse inhibition in rat hippocampus: dependence on GABA(A) receptor α4 subunit upregulation. J Neurophysiol 89: 186–198, 2003. doi:10.1152/jn.00195.2002.

38. Hunter SK. Performance fatigability: mechanisms and task specificity. Cold Spring Harb Perspect Med 8: a029728, 2018. doi:10.1101/cshperspect.a029728.

39. Inghilleri M, Conte A, Currà A, Frasca V, Lorenzano C, Berardelli A. Ovarian hormones and cortical excitability. An rTMS study in humans. Clin Neurophysiol 115: 1063–1068, 2004. doi:10.1016/j.clinph.2003.12.003.

40. Janse de Jonge XA, Boot CR, Thom JM, Ruell PA, Thompson MW. The influence of menstrual cycle phase on skeletal muscle contractile characteristics in humans. J Physiol 530: 161–166, 2001. doi:10.1111/j.1469-7793.2001.0161m.x.

41. Jasmin L, Rabkin SD, Granato A, Boudah A, Ohara PT. Analgesia and hyperalgesia from GABA-mediated modulation of the cerebral cortex. Nature 424: 316–320, 2003. doi:10.1038/nature01808.

42. Kavanagh JJ, McFarland AJ, Taylor JL. Enhanced availability of serotonin increases activation of unfatigued muscle but exacerbates central fatigue during prolonged sustained contractions. J Physiol 597: 319–332, 2019. doi:10.1113/JP277148.

43. Keller A. Intrinsic synaptic organization of the motor cortex. Cereb Cortex 3: 430–441, 1993. doi:10.1093/cercor/3.5.430.

44. Klass M, Roelands B, Meeusen R, Duchateau J. Acute effect of noradrenergic modulation on motor output adjustment in men. Med Sci Sports Exerc 50: 1579–1587, 2018. doi:10.1249/MSS.0000000000001622.

45. Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15: 155–163, 2016. [Erratum in J Chiropr Med 16: 346, 2017]. doi:10.1016/j.jcm.2016.02.012.

46. Kubo K, Miyamoto M, Tanaka S, Maki A, Tsunoda N, Kanehisa H. Muscle and tendon properties during menstrual cycle. Int J Sports Med 30: 139–143, 2009. doi:10.1055/s-0028-1104573.

47. McEwen BS. Invited review: Estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol (1985) 91: 2785–2801, 2001. doi:10.1152/jappl.2001.91.6.2785.

48. Merton PA. Voluntary strength and fatigue. J Physiol 123: 553–564, 1954. doi:10.1113/jphysiol.1954.sp005070.

49. Phillips SK, Sanderson AG, Birch K, Bruce SA, Woledge RC. Changes in maximal voluntary force of human adductor pollicis muscle during the menstrual cycle. J Physiol 496: 551–557, 1996. doi:10.1113/jphysiol.1996.sp021706.

50. Place N, Maffiuletti NA, Martin A, Lepers R. Assessment of the reliability of central and peripheral fatigue after sustained maximal voluntary contraction of the quadriceps muscle. Muscle Nerve 35: 486–495, 2007. doi:10.1002/mus.20714.

51. Rekling JC, Funk GD, Bayliss DA, Dong XW, Feldman JL. Synaptic control of motoneuronal excitability. Physiol Rev 80: 767–852, 2000. doi:10.1152/physrev.2000.80.2.767.

52. Säisänen L, Pirinen E, Teitti S, Könönen M, Julkunen P, Määttä S, Karhu J. Factors influencing cortical silent period: optimized stimulus location, intensity and muscle contraction. J Neurosci Methods 169: 231–238, 2008. doi:10.1016/j.jneumeth.2007.12.005.

53. Sarwar R, Niclos BB, Rutherford OM. Changes in muscle strength, relaxation rate and fatiguability during the human menstrual cycle. J Physiol 493: 267–272, 1996. doi:10.1113/jphysiol.1996.sp021381.

54. Schultz KN, von Esenwein SA, Hu M, Bennett AL, Kennedy RT, Musatov S, Toran-Allerand CD, Kaplitt MG, Young LJ, Becker JB. Viral vector-mediated overexpression of estrogen receptor-α in striatum enhances the estradiol-induced motor activity in female rats and estradiol-modulated GABA release. J Neurosci 29: 1897–1903, 2009. doi:10.1523/JNEUROSCI.4647-08.2009.

55. Sherman BM, Korenman SG. Hormonal characteristics of the human menstrual cycle throughout reproductive life. J Clin Invest 55: 699–706, 1975. doi:10.1172/JCI107979.

56. Smith MJ, Adams LF, Schmidt PJ, Rubinow DR, Wassermann EM. Effects of ovarian hormones on human cortical excitability. Ann Neurol 51: 599–603, 2002. doi:10.1002/ana.10180.

57. Smith MJ, Keel JC, Greenberg BD, Adams LF, Schmidt PJ, Rubinow DA, Wassermann EM. Menstrual cycle effects on cortical excitability. Neurology 53: 2069–2072, 1999. doi:10.1212/WNL.53.9.2069.

58. Smith SS. Estrogen administration increases neuronal responses to excitatory amino acids as a long-term effect. Brain Res 503: 354–357, 1989. doi:10.1016/0006-8993(89)91691-0.

59. Smith SS, Waterhouse BD, Chapin JK, Woodward DJ. Progesterone alters GABA and glutamate responsiveness: a possible mechanism for its anxiolytic action. Brain Res 400: 353–359, 1987. doi:10.1016/0006-8993(87)90634-2.

60. Smith SS, Woodward DJ, Chapin JK. Sex steroids modulate motor-correlated increases in cerebellar discharge. Brain Res 476: 307–316, 1989. doi:10.1016/0006-8993(89)91251-1.

61. Smith SS, Woolley CS. Cellular and molecular effects of steroid hormones on CNS excitability. Cleve Clin J Med 71, Suppl 2: S4–S10, 2004. doi:10.3949/ccjm.71.Suppl_2.S4.

62. Stoffel-Wagner B. Neurosteroid metabolism in the human brain. Eur J Endocrinol 145: 669–679, 2001. doi:10.1530/eje.0.1450669.

63. Tamm AS, Lagerquist O, Ley AL, Collins DF. Chronotype influences diurnal variations in the excitability of the human motor cortex and the ability to generate torque during a maximum voluntary contraction. J Biol Rhythms 24: 211–224, 2009. doi:10.1177/0748730409334135.

64. Tenan MS, Hackney AC, Griffin L. Maximal force and tremor changes across the menstrual cycle. Eur J Appl Physiol 116: 153–160, 2016. doi:10.1007/s00421-015-3258-x.

65. Tenan MS, Peng YL, Hackney AC, Griffin L. Menstrual cycle mediates vastus medialis and vastus medialis oblique muscle activity. Med Sci Sports Exerc 45: 2151–2157, 2013. doi:10.1249/MSS.0b013e318299a69d.

66. Thomas K, Goodall S, Howatson G. Performance fatigability is not regulated to a peripheral critical threshold. Exerc Sport Sci Rev 46: 240–246, 2018. doi:10.1249/JES.0000000000000162.

67. Todd G, Gorman RB, Gandevia SC. Measurement and reproducibility of strength and voluntary activation of lower-limb muscles. Muscle Nerve 29: 834–842, 2004. doi:10.1002/mus.20027.

68. Todd G, Taylor JL, Gandevia SC. Measurement of voluntary activation of fresh and fatigued human muscles using transcranial magnetic stimulation. J Physiol 551: 661–671, 2003. doi:10.1113/jphysiol.2003.044099.

69. Vincent K, Stagg CJ, Warnaby CE, Moore J, Kennedy S, Tracey I. "Luteal analgesia": progesterone dissociates pain intensity and unpleasantness by influencing emotion regulation networks. Front Endocrinol (Lausanne) 9: 413, 2018. doi:10.3389/fendo.2018.00413.

70. Wallis CJ, Luttge WG. Influence of estrogen and progesterone on glutamic acid decarboxylase activity in discrete regions of rat brain. J Neurochem 34: 609–613, 1980. doi:10.1111/j.1471-4159.1980.tb11187.x.

71. Weier AT, Pearce AJ, Kidgell DJ. Strength training reduces intracortical inhibition. Acta Physiol (Oxf) 206: 109–119, 2012. doi:10.1111/j.1748-1716.2012.02454.x.

72. Wong M, Moss RL. Long-term and short-term electrophysiological effects of estrogen on the synaptic properties of hippocampal CA1 neurons. J Neurosci 12: 3217–3225, 1992. doi:10.1523/JNEUROSCI.12-08-03217.1992.

73. Yacyshyn AF, Woo EJ, Price MC, McNeil CJ. Motoneuron responsiveness to corticospinal tract stimulation during the silent period induced by transcranial magnetic stimulation. Exp Brain Res 234: 3457–3463, 2016. doi:10.1007/s00221-016-4742-1.

74. Ziemann U, Lönnecker S, Steinhoff BJ, Paulus W. Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol 40: 367–378, 1996. doi:10.1002/ana.410400306.